AZ, J&J team up on more Imbruvica blood-cancer trials; Bayer's newly enlarged consumer unit plots agency shift;

> AstraZeneca ($AZN), Pharmacyclics ($PCYC) and Johnson & Johnson's ($JNJ) Janssen unit have teamed up to test J&J's Imbruvica in combination with an experimental AZ drug to treat blood cancers. Release

> Now that its buyout of Merck's ($MRK) consumer business is wrapped up, Bayer is planning to consolidate its agency work in the field, apparently giving all creative work to WPP and Omnicom, leaving Havas and other agencies in the cold. Report

> PDR Network has merged with LDM Group, boosting communications with doctors and pharmacies; the combined companies will reach 25,000 prescribers via electronic health records and another 800,000 prescribers through various digital channels. Report

> Sanofi ($SNY) Pasteur said the FDA approved a change to the label on Fluzone High-Dose to highlight data showing improved protection against the flu compared to the standard-dose version.Release

> Vertex Pharmaceuticals ($VRTX) filed for FDA approval for its new cystic fibrosis combination treatment pairing the already approved Kalydeco with a new drug, Lumacaftor. Release

> Novo Nordisk's ($NVO) obesity drug candidate Saxenda (liraglutide) helped patients lose weight, with reductions similar across a range of people, from simply overweight to extremely obese. Release

> Boehringer Ingelheim is plotting a big move for market share in India, with plans to bring its cancer drugs to the country next year. Report

And Finally... A new study found that a Pfizer ($PFE) anticoagulant, Fragmin, is more cost-effective in seriously ill patients, compared with unfractionated heparin. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?